Literature DB >> 31658576

Management of Glioblastoma, Present and Future.

Nancy Ann Oberheim Bush1, Shawn L Hervey-Jumper1, Mitchel S Berger2.   

Abstract

Glioblastomas are the most common malignant brain tumor and despite extensive research have a dismal prognosis. This review focuses on the current treatment paradigms of glioblastoma and highlights current advances in surgical approaches, imaging techniques, molecular diagnostics, and translational efforts. Several promising clinical trials in immunotherapy and personalized medicine are discussed and the importance of quality of life in the patients and their caregivers both during active treatment and survivorship is also commented on.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Glioblastoma; Glioma; Immunotherapy; Pharmacology; Quality of life; Review; Targeted therapy; Treatment

Year:  2019        PMID: 31658576     DOI: 10.1016/j.wneu.2019.07.044

Source DB:  PubMed          Journal:  World Neurosurg        ISSN: 1878-8750            Impact factor:   2.104


  14 in total

Review 1.  Challenges in glioblastoma immunotherapy: mechanisms of resistance and therapeutic approaches to overcome them.

Authors:  Karl John Habashy; Rana Mansour; Charbel Moussalem; Raymond Sawaya; Michel J Massaad
Journal:  Br J Cancer       Date:  2022-06-04       Impact factor: 9.075

Review 2.  Outcome of glioblastoma resection in patients 80 years of age and older.

Authors:  Mahamadou Niare; Jacques Desrousseaux; Clarissa Cavandoli; Victor Virak; Oumar Sacko; Saloua Charni; Franck-Emmanuel Roux
Journal:  Acta Neurochir (Wien)       Date:  2021-03-04       Impact factor: 2.216

3.  Patient specific, imaging-informed modeling of rhenium-186 nanoliposome delivery via convection-enhanced delivery in glioblastoma multiforme.

Authors:  Ryan T Woodall; David A Hormuth Ii; Chengyue Wu; Michael R A Abdelmalik; William T Phillips; Ande Bao; Thomas J R Hughes; Andrew J Brenner; Thomas E Yankeelov
Journal:  Biomed Phys Eng Express       Date:  2021-05-28

4.  Deficiency of G9a Inhibits Cell Proliferation and Activates Autophagy via Transcriptionally Regulating c-Myc Expression in Glioblastoma.

Authors:  Xiao Xue Ke; Rui Zhang; Xi Zhong; Lei Zhang; Hongjuan Cui
Journal:  Front Cell Dev Biol       Date:  2020-11-27

5.  The double effect of walnut septum extract (Juglans regia L.) counteracts A172 glioblastoma cell survival and bacterial growth.

Authors:  Carlo Genovese; Maria Teresa Cambria; Floriana D'angeli; Alessandro Paolo Addamo; Giuseppe Antonio Malfa; Laura Siracusa; Luana Pulvirenti; Carmelina Daniela Anfuso; Gabriella Lupo; Mario Salmeri
Journal:  Int J Oncol       Date:  2020-10-05       Impact factor: 5.650

6.  Kinesin Family Member C1 Increases Temozolomide Resistance of Glioblastoma Through Promoting DNA Damage Repair.

Authors:  Jianheng Wu; Xinjun Wang; Xiaowei Yuan; Qiao Shan; Zhen Wang; Yuehui Wu; Jingwei Xie
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

Review 7.  Advanced imaging techniques for neuro-oncologic tumor diagnosis, with an emphasis on PET-MRI imaging of malignant brain tumors.

Authors:  Wynton B Overcast; Korbin M Davis; Chang Y Ho; Gary D Hutchins; Mark A Green; Brian D Graner; Michael C Veronesi
Journal:  Curr Oncol Rep       Date:  2021-02-18       Impact factor: 5.075

8.  A Hematological-Related Prognostic Scoring System for Patients With Newly Diagnosed Glioblastoma.

Authors:  Chao Zhao; Long-Qing Li; Feng-Dong Yang; Ruo-Lun Wei; Min-Kai Wang; Di-Xiang Song; Xiao-Yue Guo; Wei Du; Xin-Ting Wei
Journal:  Front Oncol       Date:  2020-12-10       Impact factor: 6.244

9.  PSMA Expression in Glioblastoma as a Basis for Theranostic Approaches: A Retrospective, Correlational Panel Study Including Immunohistochemistry, Clinical Parameters and PET Imaging.

Authors:  Adrien Holzgreve; Annamaria Biczok; Viktoria C Ruf; Friederike Liesche-Starnecker; Katja Steiger; Maximilian A Kirchner; Marcus Unterrainer; Lena Mittlmeier; Jochen Herms; Jürgen Schlegel; Peter Bartenstein; Jörg-Christian Tonn; Nathalie L Albert; Bogdana Suchorska
Journal:  Front Oncol       Date:  2021-03-30       Impact factor: 6.244

10.  IRDye800CW labeled uPAR-targeting peptide for fluorescence-guided glioblastoma surgery: Preclinical studies in orthotopic xenografts.

Authors:  Sorel Kurbegovic; Karina Juhl; Kasper Kildegaard Sørensen; Julie Leth; Gro Linno Willemoe; Anders Christensen; Yvonne Adams; Anja Ramstedt Jensen; Christian von Buchwald; Jane Skjøth-Rasmussen; Michael Ploug; Knud J Jensen; Andreas Kjaer
Journal:  Theranostics       Date:  2021-05-21       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.